Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fecal oral route

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Fecal oral route. Displaying page 1 of 1.
    EudraCT Number: 2015-005111-32 Sponsor Protocol Number: ABO-MELI-15 Start Date*: 2016-02-24
    Sponsor Name:ABOCA S.P.A. SOCIETà AGRICOLA
    Full Title: Multicenter, Prospective, Comparative, Randomized Controlled Clinical investigation on the performance of Promelaxin® micro-enemas versus oral administration of Macrogol 4000, in the treatment of c...
    Medical condition: Chronic Functional Constipation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10067374 Stypsis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004295-55 Sponsor Protocol Number: RPC01-3204 Start Date*: 2018-03-08
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) LT (Completed) CZ (Trial now transitioned) FR (Trial now transitioned) SI (Completed) AT (Completed) BG (Trial now transitioned) DE (Trial now transitioned) GR (Completed) ES (Ongoing) SE (Prematurely Ended) NL (Ongoing) PL (Trial now transitioned) BE (Completed) IE (Trial now transitioned) GB (Not Authorised) DK (Completed) PT (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003199-11 Sponsor Protocol Number: 2013-1 Start Date*: 2015-09-25
    Sponsor Name:GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
    Full Title: Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003924-13 Sponsor Protocol Number: MK-952 004-00 Start Date*: 2006-11-14
    Sponsor Name:Merck Sharp & Dohme Ltd
    Full Title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10012271 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019267-11 Sponsor Protocol Number: MA-PA25CF10-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Axcan Pharma Inc.
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE THE SAFETY AND EFFICACY OF PANZYTRAT® 25 000 TO KREON® 25 000 IN THE CONTROL OF STEATORRHEA IN SUBJECTS AGED 7 YEARS AND OLDER WI...
    Medical condition: Correction of steathorrea associated with chronic exocrine pancreatic insufficiency in cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10033628 Pancreatic insufficiency PT
    13.1 10017947 - Gastrointestinal disorders 10041968 Steatorrhea LLT
    13.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001600-64 Sponsor Protocol Number: RPC01-3102 Start Date*: 2015-10-14
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Completed) GB (Completed) SK (Completed) HU (Trial now transitioned) BG (Trial now transitioned) NL (Completed) BE (Trial now transitioned) HR (Completed) LV (Completed) AT (Prematurely Ended) GR (Completed) ES (Prematurely Ended) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012842-21 Sponsor Protocol Number: PR-005 Start Date*: 2010-09-20
    Sponsor Name:Aptalis Pharma US Inc.
    Full Title: Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in theTreatment of Exocrine Pancreatic Insufficien...
    Medical condition: Exocrine pancreatic insufficiency associated with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10015674 Exocrine pancreas conditions HLGT
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) BG (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 13:59:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA